Efficacy and Safety of The Albumin-Bound Paclitaxel Combined with Anti-PD-1 Antibody in Pancreatic Ductal Adenocarcinoma (Adv. Therap. 9/2025)

The cover image shows a vivid dichotomy between two therapeutic landscapes. On the left, a harmonious and flourishing tumor microenvironment under combination therapy is brought to life—swallows in flight and radiant light symbolize the synergy of immune cells and cytokines. In stark contrast, the right side unveils the turmoil of PD-1 monotherapy: splattered ink evokes uncontrolled tumor growth, gnarled branches allude to immune-related adverse events, and dark birds take wing as harbingers of excessive immune infiltration—together conjuring a bleak, unsettling scene. More details can be found in the Research Article by Weimin Cai and co-workers (DOI: 2500075).